Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agriflu is an inactivated trivalent influenza virus vaccine containing purified surface antigens of influenza viruses type A and B. It is indicated for active immunization to prevent disease caused by the specific influenza virus subtypes A and type B contained in the vaccine. The vaccine works by stimulating the immune system to produce antibodies against these viral strains, thereby providing protection against seasonal influenza. Agriflu is administered as an intramuscular injection and is approved for use in adults 18 years of age and older (in the US), though it has also been indicated for persons 6 months of age and older in some regions such as Canada. The composition of Agriflu changes annually based on recommendations from health authorities to match circulating strains[2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agriflu.